CMS' Change of Heart: Niaspan will be Covered Under Medicare Part D
This article was originally published in RPM Report
The federal government reverses position on Kos' HDL-elevating agent. The decision could have long-term consequences for the evolution of the cholesterol market.
You may also be interested in...
Abbott’s decision to spin-off proprietary pharmaceuticals as a stand-alone company is all about Wall Street: investors cheered the move for “unlocking value” by removing the giant shadow cast by Humira over the diversified base business. But it is also an important touchstone for all the key public policy themes playing out in the biopharma space after health care reform.
Medicare Part D and prescription drug prices come up briefly in a brief appearance by controversial CMS head Berwick before the Senate Finance Committee.
Nothing gets biopharma policy watchers more worked up than the potential that the Centers for Medicare & Medicaid Services will second-guess FDA approval decisions. In reality, though, CMS often has no choice but to apply its own interpretation to issues that also fall under FDA's jurisdiction-and the health care reform implementation is bringing more of those cases to the fore.